Trial Profile
A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 [ispronicline] to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6, and UGT1A1 Activity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ispronicline (Primary) ; Bilirubin oxidase inhibitors; Bupropion; Caffeine; Midazolam; Omeprazole; Rosiglitazone
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 25 Nov 2008 Status changed from recruiting to completed, as reported in ClinicalTrials.gov record.
- 24 Sep 2008 Planned end date changed from 1 Jul 2008 to 1 Sep 2008 as reported by CT.gov
- 04 Jul 2008 New trial record.